PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 21 1984

SUBJECT INDEX

Acetylcholine depletion, 273
  AF64A
  ethylcholine aziridinium ion
  lesions, fimbria-fornix
  memory deficits
ACTH, 513
  blood pressure
  dishabituation
  heart rate
  human studies
  neuropeptides
  vigilance
Activity responses, 675
  castration
  nicotine
  sex differences
Adrenal gland, 125
  catecholamines
  ethanol
  urinary excretion
β-Adrenergic agonist, 313
  biting behavior
  chronic treatment
  clenbuterol
Adrenergic receptors, 417
  prenatal stress
  tyrosine hydroxylation
β-Adrenergic antagonists
  drinking, 883
  drug interaction, 883
  memory spread, 633
  propranolol, 633
  quantitative autoradiography, 633
  salt appetite, 883
Beta-adrenergic blockade, 651
  food intake inhibition
  induced feeding
  propranolol
Adrenoceptors, 267
  catalepsy
  chlorpromazine
  hypothalamus
  imipramine
  muricide
AF64A, 273
  acetylcholine depletion
  ethylcholine aziridinium ion
  lesions, fimbria-fornix
  memory deficits
Affective disorders, s49
  antidepressants
  rubidium
  schizophrenia
Age differences, 671
  apomorphine
  social isolation
  stereotypy
Aggregation, 969
  DSIP
  precursors
  protein binding
Aggression, 495
  light cycle
  naloxone
  saline drinking
  social behavior
Alcohol consumption, 387
  lithium chloride toxicosis
  odor aversion
Alcohol dehydrogenase, s35
  aldehyde dehydrogenase
  cesium chloride
  ethanol
  hepatoma
  morbidity
Aldehyde dehydrogenase
  alcohol dehydrogenase, s35
  cesium chloride, 235
  ethanol, s35
  hepatoma, s35
  lithium, s93
  morbidity, s35
  mortality, s93
  nitrogen dioxide, s93
Alkali metals
  atria, s81
  cesium, s71
  chronotropic response, s81
  contractile force, s81
  heart rate, s81
  ionophores, s77
  ion transport, s77
  lithium, s71
  polyethylene glycols, s77
  potassium, s71
  rubidium, s71
  silacrown ethers, s77
  sodium, s71
Alzheimer's disease, 169
  avoidance
  dementias
  memory
  retention
Aminergic changes, 181
  apomorphine
  chronic lithium treatment
  social isolation
Amphetamine, 97
  clozapine
  locomotor activity
  stereotypy
  thioridazine
  typical and atypical neuroleptics
Amphetamine analogs, 895
  drug discrimination
  structure-activity studies
d-Amphetamine
  body temperature, 575
  catecholamine, 321
  diazepam, 191
  fixed-interval schedules, 67
  greeting behavior, 191
  human studies, 67
  indomethacin, 219
  in vivo studies, 583
  ontogeny of rearing, 321
  operant behavior, 219, 279, 575, 583
  pigeons, 663
  prostaglandins, 219, 279, 575, 583
  rate-dependent drug effects, 67
  rectal temperature, 219
  rhesus monkeys, 191
  scopolamine, 321
  short-term memory, 663
  social behavior, 191
  time perception, 663
  verbal behavior, 67
Amphibians, 213
  dextrorphan
  drug interaction
  levorphanol
  morphine
  naloxone
  opiates
Analgesia
  anxiety, 749
  avoidance, 103
  cold pressor pain, 975
  human studies, 975
  inescapable shock, 749
  librium, 749
  MIF-1, 975
  morphine, 79
  morphine, prenatal exposure, 103
  naloxone, 681
  nociception, 133
  opiate antagonist, 937, 975
  pain, 79
  parachlorophenylalanine, 79
  PCPA, 681
  shuttle-escape deficit, 749
  stress, 103, 681
  tail-flick, 937
  threshold measurement, 133
  Tyr-MFI-1, 937

up-and-down method, 133
yohimbine, 681
Anhedonia paradigm, 617
licking
pimozide
sucrose reward
Animal model
cerebral blood flow, 891
cerebrovascular permeability, 891
depression, 487, 891
monoamines, 891
pyrazolodiazepine stress, 487
zometapine, 487
Anorexia nervosa, s51
chemotherapy-induced neutropenia
lithium
metabolizing thyroid cancer
Anti-conflict action, 521
benzodiazepine receptors
diazepam
GABA receptors
Anticonvulsant
benzodiazepines, 137
electroconvulsive shock, 491
fominoben, 137
hypothermia, 491
THIP, 491
Antidepressants
affective disorders, s49
chronic administration, 225
depression, 767
hypoactivity, 695
immobility, 767
intracerebral microinjection, 225
MIF-1, 767
muricide, 225
olfactory bulbectomy, 225
repeated treatment, antidepressants, 695
rubidium, s49
salbutamol, 695
schizophrenia, s49
Tyr-MIF-1, 767
Antimuscarinic agents, 109
drug interaction
physostigmine
schedule-controlled behavior
Antinociception
conditioned taste aversion, 591
enkephalinamide, 441
morphine, 591
naloxone, 591
opiate receptors, 591
vagal afferents, 441
Antioxidants, s7
cancer
cesium
diet
essential fatty acids
vitamins
Antipsychotic drugs, 645
brain stimulation
detection thresholds
Anxiety
analgesia, 749
benzodiazepines, 839
clorazepate, 839
inescapable shock, 749
librium, 749
plasma corticosterone, 839
RO 15-1788, 839
shuttle-escape deficit, 749
stress, 839
Anxiety model, 353
aversive brain stimulation
ethyl alcohol
periaqueductal gray
Anxiolytic agents
benzodiazepines, 965
chlordiazepoxide, 449
drinking, 965
NaCl intake, 449
punishment attenuation, 449
Apparatus
cell harvester, 947
two-bar press, 19
Apomorphine
age differences, 671
aminergic changes, 181
brain catecholamines, 733
chronic lithium treatment, 181
dopamine agonists, 237
dopamine autoreceptors, 301, 463
haloperidol, 463
inbred mice, 237
locomotor activity, 237
naloxone, 733
nigroraphe pathway, 301
open field, 85
pharmacogenetics, 237
serotonergic neurons, 301
sexual behavior, male rats, 463
social behavior, 85
social isolation, 181, 671
stereotypy, 85, 181, 237, 733
striatum, 301
Atria, s81
alkali metals
chronotropic response
contractile force
heart rate
Autoreceptors, 73
circling
locomotor asymmetries
substantia nigra
Aversive brain stimulation, 353
anxiety model
ethyl alcohol
periaqueductal gray
Avoidance
Alzheimer's disease, 169
analgesia, 103
body temperature, 561
central cholinergic receptors, 43
corticotropin-releasing factor, 707
dementias, 169
diisopropylfluorophosphate, 43
dopamine, 561
ethanol, 423
iodine-deficient diets, 561
locomotor activity, 561
memory, 43, 169
morphine, prenatal exposure, 103
naltrexone, 423
open field, 707
opiate antagonists, 423
plasma-corticosterone levels, 707
quinuclidinyl benzilate binding, 43
retention, 169
stress, 103
supersensitivity, 423

Behavioral effects
cats, 913
drinking, 259
eating, 259
lesions, unilateral brain, 913
morphine, 913
opioid peptides, 259
reward, 259
stereotypy, 913
Benzodiazepine antagonism, 381
CGS 8216
chlordiazepoxide
DRL responding
Ro 15-1788
Benzodiazepine receptors, 521
anti-conflict action
diazepam
GABA receptors
Benzodiazepines
anticonvulsant, 137
anxiety, 839
anxiolytic agent, 965
β-carboline, 667
chlordiazepoxide, 39, 667
clorazepate, 839
conflict situation, 773
constant light, 821
corticotropin (ACTH), 39
drinking, 965
drug preference, 865
FG 7142, 667
flurazepam, 865
fominoben, 137
hexobarbitone sleeping time, 39
human studies, 865
pineal, 821
plasma corticosterone, 839
Ro 15-1788, 839
self-stimulation, 667
self-stimulation, hypothalamus, 773
stimulation, dorsal central gray, 773
stress, 839
subjective effects, 865
superior cervical ganglionectomy, 821
Bibliography, s113
cesium
Bicuculline, 145
inferior colliculus
medial septum
site injections
substantia nigra
thyrotropin releasing hormone
Biogenic amines, 289
2-chloroadenosine
respiratory depression
Biting behavior, 313
β-adrenergic agonist
chronic treatment
clenbuterol
Blocking, 9
dorsal noradrenergic bundle
drug interaction
selective attention
Blood, 761
delta-sleep inducing peptide
high performance liquid chromatography
sleep
Blood-brain barrier, 943
carrier-mediated transport
N-tyrosinated peptides
Blood ethanol levels, 255
ethanol self-selection
operant conditioning
Blood pressure
ACTH, 513
carbon monoxide, s103
carboxyhemoglobin, s103
dishabituation, 513
heart rate, 103, 513
human studies, 513

neuropeptides, 513
respiration rate, s103
vigilance, 513
Blood pressure response, 393
passive avoidance
vasopressin
vasopressin fragments
vasopressor antagonists
Body temperature
d-amphetamine, 575
avoidance, 561
bombesin, 197
dopamine, 561
iodine-deficient diets, 561
locomotor activity, 197, 561
neurotensin, 197
open field, 197
operant behavior, 575
prostaglandins, 575
Body weight, 801
chronic drug injections
eating
hyperphagia
norepinephrine
paraventricular nucleus
Bombesin, 197
body temperature
locomotor activity
neurotensin
open field
Brain
amygdala, 225, 339
basal ganglia, 791
blood brain barrier, 177, 891
caudate nucleus, 29, 913, 929
central gray, 773
central nervous system, 145, 349, 913
cerebellum, s87, 151, 349, 481, 591
cerebral cortex, 349, 417
colliculi, 349
cortex, 151, 481
cuneate nucleus, 117
dorsal noradrenergic bundle, 357
dorsal raphe, 301
fimbria-fornix, 273
forebrain loci, 645
frontal cortex, 163
globus pallidus, 825
hippocampus, s87, 273, 301, 339, 481, 591
hypothalamus, 267, 339, 357, 481, 591, 645, 667, 773, 801
inferior colliculus, 145
lateral preoptic area, 267
locus coeruleus, 357, 891
medial forebrain bundle, 567
medulla-pons, 591
mesencephalic reticular formation, 853
mesencephalon, 339
midbrain, 481, 591
midbrain loci, 645
neocortex, 471
neostriatum, 929
nucleus accumbens, 501
paraventricular nucleus, 801
periaqueductal gray, 353, 853
pons-medulla, 349, 481
prefrontal cortex, 591
septum, 145
spinal cord, 349, 591
striatum, 53, s87, 273, 301, 339, 471, 481, 591, 853, 979
substantia nigra, 73, 89, 145, 301, 567
substantia nigra pars reticulata, 853
superior colliculus, 853
thalamus, 481
thalamus-hypothalamus, 349
vagus nerve, 441
ventral tegmental area, 567
Brain catecholamines, 733
apomorphine
naloxone
stereotypy
Brain monoamines
cholecystokinin octapeptide, 339
eating, 339
hypothalamic norepinephrine, 339
learned helplessness, 481
pituitary-gonadal axis, 481
Brain plasticity, 349
differentially-housed mice
neurotransmitter amino acids
Brain regions, s87
cesium
lithium
pharmacokinetics
rubidium
Brain stimulation, 645
antipsychotic drugs
detection thresholds
Brain-stimulation reward, 961
pentazocine
threshold determination
tripelennamine

Caffeine
drug interaction, 375
eating, 33
exploration, 871
methylxanthines, 375
naloxone, 33
nicotine, 871
open field, 871
opioids, 33
L-phenylisopropyladenosine, 375
purines, 33
tolerance, 871
variable ratio, 375
wheelrunning, 871
Cancer
antioxidants, s7
cesium, s7, s11, s25
colon carcinoma, s25
diet, s7, s11, s25
essential fatty acids, s7
human studies, s11
pH therapy, s25
vitamins, s7, s11
Cancer therapy, s1
cesium
high pH
human studies
tumors
vitamins
Cannabinoids, 61
drug discrimination
hypothermia
stereoisomers
β-Carboline, 667
benzodiazepine
chlordiazepoxide
FG 7142
self-stimulation
Carbon monoxide
blood pressure, s103
carboxyhemoglobin, s103
coronary flow, s99
heart rate, s99, s103
pulse pressure, s99
respiration rate, s103
Carboxyhemoglobin, s103
blood pressure
carbon monoxide
heart rate
respiration rate
Carrier-mediated transport, 943
blood-brain barrier
N-tyrosinated peptides
Castration, 675
activity responses
nicotine
sex differences
Catalepsy
adrenoceptors, 267
chlorpromazine, 267
GABA mechanisms, 825
globus pallidus, 825
hypothalamus, 267
imipramine, 267
locomotor activity, 825
muricide, 267
stereotypy, 825
Catecholamines
adrenal gland, 125
d-amphetamine, 321
ethanol, 125
ontogeny of rearing, 321
scopolamine, 321
urinary excretion, 125
(+)-Cathine, 1
(±)-cathinone
drug discrimination
drug interaction
structure-activity relationships
(±)-Cathinone, 1
(+)-cathine
drug discrimination
drug interaction
structure-activity relationships
Cats
behavioral effects, 913
cuneate nucleus, 117
dependence, 929
EEG, 923
electrical stimulation, 117
lesions, caudate nuclei, 929
lesions, unilateral brain, 913
morphine, 913, 923, 929
push-pull perfusion, 117
sleep-wakefulness, 923
stereotypy, 913
superficial radial nerve, 117
tolerance, 929
Caudate nucleus, 29
6-hydroxydopamine
methylamphetamine
neurotoxicity
Cell harvester, 947
filtration
opiate receptors
Central cholinergic receptors, 43
avoidance
diisopropylfluorophosphate
memory
quinuclidinyl benzilate binding
Cerebellum, 151
convulsants
cortex
depressants
drug interaction
GABA receptor complex
Cerebral blood flow, 891
animal model

cerebrovascular permeability
depression
monoamines
Cerebrovascular permeability, 891
animal model
cerebral blood flow
depression
monoamines
Cesium
alkali metals, s71
antioxidants, s7
bibliography, s113
brain regions, s87
cancer, s7, s11, s25
cancer therapy, s1
cesium antipsychotic synergism, s17
cesium glucose interaction, s17
cesium vasopressor activity, s17
colon carcinoma, s25
diet, s7, s11, s15, s25
essential fatty acids, s7
hepatoma, s31
high pH, s1
human studies, s1, s11, s15
lithium, s71, s87
mortality, s27, s31
pharmacokinetics, s87
pH therapy, s25
positron radiodetection, s17
potassium, s27, s31, s71
potassium supplement, s15
rubidium, s71, s87
sarcoma, s27
sodium, s71
tumor, s1, s27
vitamins, s1, s7, s11, s15
Cesium antipsychotic synergism, s17
cesium
cesium glucose interaction
cesium vasopressor activity
positron radiodetection
Cesium chloride, s35
alcohol dehydrogenase
aldehyde dehydrogenase
ethanol
hepatoma
morbidity
Cesium glucose interaction, s17
cesium
cesium antipsychotic synergism
cesium vasopressor activity
positron radiodetection
Cesium vasopressor activity, s17
cesium
cesium antipsychotic synergism
cesium glucose interaction
positron radiodetection
CGS 8216, 381
benzodiazepine antagonism
chlordiazepoxide
DRL responding
Ro 15-1788
Chafing, 727
displacement activity
fish
naloxone
neuropeptides
thyrotropin-releasing hormone (TRH)
Chemotherapy-induced neutropenia, s51
anorexia nervosa
lithium
metabolizing thyroid cancer
Chloral hydrate, 599
flash evoked potentials
hyperthermia
Chlordiazepoxide
anxiolytic agents, 449
benzodiazepine antagonism, 381
benzodiazepines, 39, 667
β-carboline, 667
CGS 8216, 381
conflict, 845
corticotropin (ACTH), 39
DRL responding, 381
FG 7142, 667
GABA, 845
hexobarbitone sleeping time, 39
NaCl intake, 449
Ro 15-1788, 381
punishment attenuation, 449
self-stimulation, 667
sodium valproate, 845
2-Chloroadrenosine, 289
biogenic amines
respiratory depression
Chlorpromazine, 267
adrenoceptors
catalepsy
hypothalamus
imipramine
muricide
Chlorprothixene, 721
delayed-matching-to-sample
haloperidol
neuroleptic drugs
pigeons
trifluoperazine
Cholecystokinin, 755
lordosis
sexual behavior, female rats
Cholecystokinin octapeptide, 339
brain monoamines
eating
hypothalamic norepinephrine
Choline, 209
habituation
memory
nootropics
piracetam
Chronic administration, 225
antidepressants
intracerebral microinjection
muricide
olfactory bulbectomy
Chronic drug injections, 801
body weight
eating
hyperphagia
norepinephrine
paraventricular nucleus
Chronic lithium treatment, 181
aminergic changes
apomorphine
social isolation
Chronic treatment, 313
β-adrenergic agonist
biting behavior
clenbuterol
Chronotropic response, s81
alkali rate
atria
contractile force
heart rate
Cigarettes
human studies, 203, 903
magnitude estimation, 203
nicotine, 203
preference, 203
self-administration, 903
smoking, 903
taste, 203
temperature, 903
Circadian cycle, 47
drinking
ethylketocyclazocine
water-deprivation
Circling
autoreceptors, 73
GABA agonists, 853
locomotor asymmetries, 73
substantia nigra, 73
superior colliculus, 853
Clenbuterol, 313
β-adrenergic agonist
biting behavior
chronic treatment
Clorazepate, 839
anxiety
benzodiazepines
plasma corticosterone
Ro 15-1788
stress
Clozapine, 97
amphetamine
locomotor activity
stereotypy
thioridazine
typical and atypical neuroleptics
Cognition, 231
diazepam
learning
memory
psychomotor performance
route of administration
Cold pressor pain, 975
analgesia
human studies
MIF-1
opiate antagonist
Cold swim stress, 813
diazepam
flinch jump test
nociceptive thresholds
stress-induced analgesia
Colon carcinoma, s25
cancer
cesium
diet
pH therapy
Computerized bibliographic retrieval, s109
information systems
lithium
Conditioned emotional response, 357
dorsal noradrenergic bundle
lesions, electrolytic
locus coeruleus
open field
Conditioned place preference, 545
drug reinforcement
morphine extinction
Conditioned taste aversion, 591
antinociception
morphine
naloxone
opiate receptors
Conflict, 845
chlordiazepoxide
GABA
sodium valproate
Conflict situation, 773
benzodiazepines
self-stimulation, hypothalamus
stimulation, dorsal central gray
Constant light, 821
benzodiazepines

pineal
superior cervical ganglionectomy
Contractile force, s81
alkali metals
atria
chronotropic response
heart rate
Contraversive circling, 567
electrical stimulation, medial forebrain bundle
locomotor activity
stimulus parameters
Convulsants, 151
cerebellum
cortex
depressants
drug interaction
GABA receptor complex
Coronary flow, s99
carbon monoxide
heart rate
pulse pressure
Cortex, 151
cerebellum
convulsants
depressants
drug interaction
GABA receptor complex
Corticotropin (ACTH), 39
benzodiazepines
chlordiazepoxide
hexobarbitone sleeping time
Corticotropin-releasing factor, 707
avoidance
open field
plasma-corticosterone levels
Cuneate nucleus, 117
cats
electrical stimulation
push-pull perfusion
superficial radial nerve
Cysteamine, 833
locomotor activity
open field
somatostatin

DA synthesis, 345
morphine withdrawal
Z-Pro-D-Leu
Delayed-matching-to-sample, 721
chlorprothixene
haloperidol
neuroleptic drugs
pigeons
trifluoperazine
Delta-sleep inducing peptide, 761
blood
high performance liquid chromatography
sleep
Dementias, 169
Alzheimer's disease
avoidance
memory
retention
Dependence, 929
cats
lesions, caudate nuclei
morphine
tolerance
Depressant effects, 409
diazepam
drug discrimination
fixed ratio schedule
tolerance
Depressants, 151
cerebellum
convulsants
cortex
drug interaction
GABA receptor complex
Depression
animal model, 487, 891
antidepressant drugs, 767
cerebral blood flow, 891
cerebrovascular permeability, 891
immobility, 767
MIF-1, 767
Tyr-MIF-1, 767
monoamines, 891
pyrazolodiazepine stress, 487
zometapine, 487
Desensitization, 177
drug interaction
locomotor activity
beta-receptor agonists
tachyphylaxis
Detection thresholds, 645
antipsychotic drugs
brain stimulation
Dexamphetamine, 53
excitatory afferents
multi-unit activity
striatum
Dextrorphan, 213
amphibians
drug interaction
levorphanol
morphine
naloxone
opiates
Diallel cross, 953
hypothermia
nicotine
pharmacogenetics
strain differences
Diazepam
d-amphetamine, 191
anti-conflict action, 521
benzodiazepine receptors, 521
cognition, 231
cold swim stress, 813
depressant effects, 409
drug discrimination, 409
fixed ratio schedule, 409
flinch jump test, 813
GABA receptors, 521
greeting behavior, 191
learning, 231
memory, 231
nociceptive thresholds, 813
psychomotor performance, 231
rhesus monkeys, 191
route of administration, 231
social behavior, 191
stress-induced analgesia, 813
tolerance, 409
Diet
antioxidants, s7
cancer, s7, s11, s25
cesium, s7, s11, s15, s25
colon carcinoma, s25
essential fatty acids, s7
human studies, s11, s15
pH therapy, s25
potassium supplement, s15
vitamins, s7, s11, s15
Differentially-housed mice, 349
brain plasticity
neurotransmitter amino acids
Diisopropyl fluorophosphate
avoidance, 43
central cholinergic receptors, 43
memory, 43, 467
muscarinic receptors, 467
quinuclidinyl benzilate binding, 43
[^{3}H] quinuclidinyl benzilate binding, 43
retention, 467
Discrimination, 19
drug discrimination
fixed-ratio schedule
two-bar press
Dishabituation, 513
ACTH
blood pressure
heart rate
human studies
neuropeptides
vigilance
Displacement activity, 727
chafing
fish
naloxone
neuropeptides
thyrotropin-releasing hormone (TRH)
DOM
drug interaction, 281, 333
lisuride, 281
LSD, 281, 333
mescaline, 281
naloxone, 333
operant behavior, 281, 333
quipazine, 333
Dopamine
avoidance, 561
body temperature, 561
estrogen, 791
iodine-deficient diets, 561
locomotor activity, 561, 791
postural deviation, 791, 979
rotation, 791, 979
striatum, 979
Dopamine agonists, 237
apomorphine
inbred mice
locomotor activity
pharmacogenetics
stereotypy
Dopamine autoreceptors
apomorphine, 301, 463
haloperidol, 463
nigroraphe pathway, 301
serotonergic neurosis, 301
sexual behavior, male rats, 463
striatum, 301
Dopamine receptors
drug discrimination, 185
lisuride, 185
muscarinic receptors, 297
nicotinic receptors, 297
tongue protruding, 297
yawning, 297
Dorsal noradrenergic bundle
blocking, 9
conditioned emotional response, 357
drug interaction, 9
lesions, electrolytic, 357
locus coeruleus, 357
open field, 357
selective attention, 9
Dorsomedial hypothalamic lesions, 245
eating

growth retardation
pancreatic enzymes
Drinking
β-adrenergic antagonists, 883
anxiolytic agent, 965
behavioral effects, 259
benzodiazepines, 965
circadian cycle, 47
drug interaction, 883, 965
ethylketocyclazocine, 47
GABA, 787
homotaurine, 787
opioid peptides, 259
reward, 259
salt appetite, 883
voluntary intake of ethanol, 787
water-deprivation, 47
DRL responding, 381
benzodiazepine antagonism
CGS 8216
chlordiazepoxide
Ro 15-1788
Drug
AF64A, 273
2-aminoindane, 895
2-aminotetralin, 895
amitriptyline, 225
amphetamine, 97, 567, 641, 687, 715, 791, 895
d-amphetamine, 67, 73, 185, 191, 219, 321, 431, 575, 583, 663, 727, 733
apomorphine, 73, 85, 181, 185, 237, 297, 301, 459, 463, 501, 561, 567, 671
arecoline hydrobromide, 169
atropine, 109, 267
baclofen, 89
bicuculline, 145, 521, 825, 845, 853
bicuculline methiodide, 89
bromazepam, 773
bromocriptine, 185
butoxamine, 883
[^{35}S]t-butylticyclophosphorothionate, 151
caffeine, 33, 375, 871
carbachol, 501
carbon monoxide, s99, s103
(+)-cathine, 1
cathinone, 185, 895
(±)-cathinone, 1
R(+)-cathinone, 1
S(−)-cathinone, 1
cesium, s1, s7, s11, s15, s17, s25, s27, s31, s71, s81, s87, s113
cesium chloride, s35
CGS 8216, 381, 965
chloral hydrate, 599
chlordiazepoxide, 39, 381, 449, 667, 749, 845
2-chloroadenosine, 289
p-chlorophenylalanine, 859
chlorpromazine, 225, 267, 431
chlorprothixene, 721
choline, 209
clenbuterol, 177, 313
clomipramine, 695
clonidine, 181
clorazepate, 839
clozapine, 97, 501, 645
cocaine, 185
cysteamine, 833
2-deoxy-D-glucose, 651
desipramine, 225
dexamphetamine, 53
dextrorphan, 213
diazepam, 191, 225, 231, 409, 431, 501, 521, 695, 773, 813, 865
α-dihydropicrotoxinin, 151
diisopropylfluorophosphate, 43, 467
DKJ-21, 109
DOM, 281, 333
L-DOPA, 459
dopamine, 73, 185, 463, 583, 791, 979
DSP-4, 163
ethanol, s35, s87, 125, 255, 317, 329, 353, 387, 423, 521, 609, 787
ethylketocyclazocine, 47
[^{3}H]-fentanyl, 705
FG 7142, 667
^{3}H-flunitrazepam, 137
fluoxetine, 533
alpha-flupenthixol, 73
flurazepam, 865
fominoben, 137
francium, s71
haloperidol, 185, 297, 463, 501, 567, 645, 695, 721
hexamethonium, 527
hexobarbitone, 39
homotaurine, 787
6-hydroxydopamine, 459
5-hydroxytryptamine, 333
imipramine, 267
indomethacin, 219
insulin, 651
isopropylbicyclophosphate ester, 151
isoproterenol, 9, 177, 883
ketocyclazocine, 651
levorphanol, 213
lisuride, 185, 281, 501
lithium, s49, s51, s57, s65, s71, s81, s87, s93, s109, 181
lithium chloride, 387
lorazepam, 865
LSD, 281, 333, 501
LY136596, 779
LY150720, 779
lysine vasopressin, 539
marijuana, 641
MDA, 453
mecamylamine, 297, 527
3-mercaptoproprionic acid, 137
mescaline, 281
methadone, 555, 743
methamphetamine, 737
methylamphetamine, 29
methylatropine, 109
methylphenidate, 641
methylscopolamine, 297
α-methyl-p-tyrosine, 345, 567, 859
methylxanthine, 375
metronidazole, 317
mianserin, 695
midazolam, 965
MIF, 365
morphiceptin, 705
morphine, 79, 103, 133, 213, 259, 365, 369, 431, 545, 555, 591, 705, 779, 913, 923, 929, 937, 975
Mr 2266, 507
Mr-2266BS, 47
muscimol, 89, 825, 845, 853
naloxone, 5, 33, 47, 213, 259, 289, 333, 365, 441, 495, 507, 591, 651, 681, 699, 727, 733, 779, 937
[^{3}H]naloxone, 705
naltrexone, 369, 423
nialamide, 695
nicotine, 203, 527, 675, 871, 953
nitrogen dioxide, s93
norepinephrine, 459, 801
ORG 2766, 513
oxotremorine, 133
parachlorophenylalanine, 79
paraxanthine, 375
PCP, 159
PCPA, 681
penbutolol, 177
pentamethylenetetrazole, 151
pentazocine, 877, 961
pentobarbital, 151, 431, 687
pentylenetetrazol, 137
phencyclidine, 401, 453
phenylisopropyladenosine, 289
phenobarbital, 19, 687
L-phenylisopropyladenosine, 375
physostigmine, 109, 297, 551
picrotoxin, 89, 501, 521, 825, 845, 853, 883
picrotoxinin, 151
pilocarpine, 297
pimozide, 97, 345, 617
piracetam, 209
pirenperone, 185
potassium, s1, s7, s27, s31, s71, s77, s81
practolol, 177
propranolol, 9, 177, 267, 633, 651
puromycin, 633
quipizine, 185, 333, 533
reserpine, 567, 641
Ro 5-4864, 821
Ro 15-1788, 137, 381, 521, 839, 845, 965
rubidium, s1, s7, s49, s71, s81, s87
salbutamol, 177, 695, 883
scopolamine, 297, 321, 471
serotonin, 79, 401
sodium, s7, s71, s77
sodium chloride, 965
sodium valproate, 845
spiperone, 825
sulpiride, 501
Δ^9-tetrahydrocannabinol (THC), 61, 641
3′-hydroxy-Δ^9-tetrahydrocannabinol, 61
theobromine, 375
theophylline, 289, 375
thioridazine, 97
toluene, 625
trifluoperazine, 721
tripelennamine, 877, 961
yohimbine, 9, 681
zinc, s25
Z-Pro-D-Leu, 345
zometapine, 487
Drug discrimination
amphetamine analogs, 895
cannabinoids, 61
(+)-cathine, 1
(±)-cathinone, 1
depressant effects, 409
diazepam, 409
discrimination, 19
dopamine receptors, 185
drug interaction, 1, 877
fixed-ratio schedule, 19, 409
hypothermia, 61
lisuride, 185
mu-receptor, 877
pentazocine, 877
stereoisomers, 61
structure-activity relationships, 1
structure-activity studies, 895
tolerance, 409

tripelennamine, 877
two-bar press, 19
Drug interaction
β-adrenergic antagonists, 883
amphibians, 213
antimuscarinic agents, 109
anxiolytic agent, 965
benzodiazepines, 965
blocking, 9
caffeine, 375
(+)-cathine, 1
(±)-cathinone, 1
cerebellum, 151
convulsants, 151
cortex, 151
depressants, 151
desensitization, 177
dextrorphan, 213
DOM, 281, 333
dorsal noradrenergic bundle, 9
drinking, 883, 965
drug discrimination, 1, 877
exteroceptive stimuli, 687
GABA receptor complex, 151
generalization, 687
incremental repeated acquisition, 431
interoceptive stimuli, 687
learning, 431
lever press, 431
levorphanol, 213
lisuride, 281
locomotor activity, 177, 501
LSD, 281, 333
mescaline, 281
methylxanthines, 375
morphiceptine, 705
morphine, 213, 705
naloxone, 213, 333
nucleus accumbens, 501
operant behavior, 281, 333
opiates, 213
pentazocine, 877
L-phenylisopropyladenosine, 375
physostigmine, 109
picrotoxin, 501
pigeons, 687
quipazine, 333
beta-receptor agonists, 177
μ-receptor, 705, 877
salt appetite, 883
schedule-controlled behavior, 109
selective attention, 9
structure-activity relationships, 1
tachyphylaxis, 177
tripelennamine, 877
variable ratio, 375
Drug preference, 865
benzodiazepines
flurazepam
human studies
subjective effects
Drug reinforcement, 545
conditioned place preference
morphine extinction
DSIP, 969
aggregation
precursors
protein binding
DSP-4, 163
lateralization
spontaneous hyperactivity

Earthworm wash, 655
chemoattractant
isolation
snakes
vomeronasal system
Eating
behavioral effects, 259
body weight, 801
brain monoamines, 339
caffeine, 33
cholecystokinin octapeptide, 339
chronic drug interactions, 801
dorsomedial hypothalamic lesions, 245
growth retardation, 245
hyperphagia, 801
hypothalamic norepinephrine, 339
naloxone, 33
norepinephrine, 801
opioid peptides, 259
opioids, 33
pancreatic enzymes, 245
paraventricular nucleus, 801
purines, 33
reward, 259
EEG, 923
cats
morphine
sleep-wakefulness
Electrical stimulation, 117
cats
cuneate nucleus
push-pull perfusion
superficial radial nerve
Electrical stimulation, medial forebrain bundle, 567
contraversive circling
locomotor activity
stimulus parameters
Electroconvulsive shock, 491
anticonvulsion
hypothermia
THIP
Elements, s41
metals
poisoning
psychiatry
Endorphins, 699
focal brain stimulation
opiate withdrawal
stimulation-produced analgesia
tolerance
Enkephalinamide, 441
antinociception
vagal afferents
Escape, 809
locomotor activity
passive avoidance
Tyr-MIF-1-analogs
Essential fatty acids, s7
antioxidants
cancer
cesium
diet
vitamins
Estrogen, 791
dopamine
locomotor activity
postural deviation
rotation
Ethanol
adrenal gland, 125
alcohol dehydrogenase, s35
aldehyde dehydrogenase, s35
anxiety model, 353
aversive brain stimulation, 353
avoidance, 423
catecholamines, 125
cesium chloride, s35
hepatoma, s35
intravenous infusion, 609
metronidazole, 317
morbidity, s35
naltrexone, 423
neural tolerance, 317
neurohypophyseal peptides, 539
opiate antagonists, 423
periaqueductal gray, 353
reinforcement, 609
self-administration, 609
strain differences, 317
supersensitivity, 423
tolerance, 539
urinary excretion, 125
Ethanol self-selection, 255
blood ethanol levels
operant conditioning
Ethylcholine aziridinium ion, 273
acetylcholine depletion
AF64A
lesions, fimbria-fornix
memory deficits
Ethylketocyclazocine, 47
circadian cycle
drinking
water-deprivation
Excitatory afferents, 53
dexamphetamine
muiti-unit activity
striatum
Exploratory behavior
caffeine, 871
habituation, 859
indoleamines, 859
monoamines, 859
nicotine, 871
open field, 871
tolerance, 871
vasopressin, 859
wheelrunning, 871
Exteroceptive stimuli, 687
drug interaction
generalization
interoceptive stimuli
pigeons
Extinction, 533
fluoxetine
quipazine
serotonin

FG 7142, 667
benzodiazepine
β-carboline
chlordiazepoxide
self-stimulation
Filtration, 947
cell harvester
opiate receptors
Fish, 727
chafing
displacement activity
naloxone
neuropeptides
thyrotropin-releasing hormone (TRH)
Fixed-interval schedules, 67
d-amphetamine
human studies
rate-dependent drug effects
verbal behavior
Fixed-ratio schedule
depressant effects, 409
diazepam, 409

discrimination, 19
drug discrimination, 19, 409
methadone, 743
multiple fixed-interval, 743
tolerance, 409
two-bar press, 19
Flash evoked potentials, 599
chloral hydrate
hyperthermia
Flinch jump test, 813
cold swim stress
diazepam
nociceptive thresholds
stress-induced analgesia
Flurazepam, 865
benzodiazepines
drug preference
human studies
subjective effects
Fluoxetine, 533
extinction
quipazine
serotonin
Focal brain stimulation, 699
endorphins
opiate withdrawal
stimulation-produced analgesia
tolerance
Fominoben, 137
anticonvulsant
benzodiazepines
Food intake inhibition, 651
beta-adrenergic blockade
induced feeding
propranolol

GABA
chlordiazepoxide, 845
conflict, 845
drinking, 787
homotaurine, 787
sodium valproate, 845
voluntary intake of ethanol, 787
GABA agonists
circling, 853
muscimol, 89
self-injurious behavior, 89
self-mutilation, 89
superior colliculus, 853
GABA mechanisms, 825
catalepsy
globus pallidus
locomotor activity
stereotypy
GABA receptor complex, 151
cerebellum
convulsants
cortex
depressants
drug interaction
GABA receptors, 521
anti-conflict action
benzodiazepine receptors
diazepam
Gastrointestinal transit, 365
MIF
morphine
naloxone
narcotic antagonism
Generalization, 687
drug interaction
exteroceptive stimuli
interoceptive stimuli
pigeons
Genetic influences, 159
PCP-induced stimulation
strain differences
Globus pallidus, 825
catalepsy
GABA mechanisms
locomotor activity
stereotypy
Greeting behavior, 191
d-amphetamine
diazepam
rhesus monkeys
social behavior
Growth retardation, 245
dorsomedial hypothalamic lesions
eating
pancreatic enzymes

Habituation
choline, 209
exploratory behavior, 859
indoleamines, 859
locomotor activity, 551
memory, 209
monoamines, 859
motility, 551
nootropics, 209
piracetam, 209
physostigmine, 551
spectral analysis, 551
vasopressin, 859
Haloperidol
apomorphine, 463
chlorprothixene, 721
delayed-matching-to-sample, 721
dopamine autoreceptors, 463
neuroleptic drugs, 721
pigeons, 721
sexual behavior, male rats, 463
trifluoperazine, 721
Hamsters, 369
locomotor activity
opiates
sex differences, hamsters
Heart rate
ACTH, 513
alkali metals, s81
atria, s81
blood pressure, s103, 513
carbon monoxide, s99, s103
carboxyhemoglobin, s103
chronotropic response, s81
contractile force, s81
coronary flow, s99
dishabituation, 513
human studies, 513
neuropeptides, 513
pulse pressure, s99
respiration rate, s103
vigilance, 513
Hepatoma
alcohol dehydrogenase, s35
aldehyde dehydrogenase, s35
cesium, s31
cesium chloride, s35
ethanol, s35
morbidity, s35
mortality, s31
potassium, s31
Hexobarbitone sleeping time, 39
benzodiazepines
chlordiazepoxide
corticotropin (ACTH)

High performance liquid chromatography, 761
blood
delta-sleep inducing peptide
sleep
High pH, s1
cancer therapy
cesium
human studies
tumors
vitamins
Homotaurine, 787
drinking
GABA
voluntary intake of ethanol
Hormone
estradiol benzoate, 791
estrogen, 755, 791
progesterone, 755
prolactin, 727
5-HT release, 401
5-HT uptake
phencyclidine
serotonergic system
stereotypy
5-HT uptake, 401
5-HT release
phencyclidine
serotonergic system
stereotypy
Human studies
ACTH, 513
d-amphetamine, 67
analgesia, 975
benzodiazepines, 865
blood pressure, 513
cancer, s11
cancer therapy, s1
cesium, s1, s11, s15
cigarettes, 203, 903
cold pressor pain, 975
diet, s11, s15
dishabituation, 513
drug preference, 865
fixed-interval schedules, 67
flurazepam, 865
heart rate, 513
high pH, s1
lithium, s65
magnitude estimation, 203
MIF-1, 975
nephrotoxicity, s65
neuropeptides, 513
neurotoxicity, s65
nicotine, 203
opiate antagonist, 975
organic brain syndrome, s65
potassium supplement, s15
preference, 203
rate-dependent drug effects, 67
self-administration, 903
smoking, 903
subjective effects, 865
taste, 203
temperature, 903
tumors, s1
verbal behavior, 67
vigilance, 513
vitamins, s1, s11, s15
Human studies, male, 329
learning
mental rehearsal
tolerance
6-Hydroxydopamine
caudate nucleus, 29

Lesch-Nyhan syndrome, 459
methylamphetamine, 29
neonatal treatment, 459
neuroleptics, 459
neurotoxicity, 29
self-mutilation, 459
Hyperphagia, 801
body weight
chronic drug injections
eating
norepinephrine
paraventricular nucleus
Hypoactivity, 695
antidepressants
repeated-treatment, antidepressants
salbutanol
Hypothalamic norepinephrine, 339
brain monoamines
cholecystokinin octapeptide
eating
Hypothalamus, 267
adrenoreceptors
catalepsy
chlorpromazine
imipramine
muricide
Hypothermia
anticonvulsion, 491
cannabinoids, 61
chloral hydrate, 599
diallel cross, 951
drug discrimination, 61
electroconvulsive shock, 491
flash evoked potentials, 599
nicotine, 953
pharmacogenetics, 953
stereoisomers, 61
strain differences, 953
THIP, 491

Imipramine, 267
adrenoceptors
catalepsy
chlorpromazine
hypothalamus
muricide
Immobility, 767
antidepressant drugs
depression
MIF-1
Tyr-MIF-1
Inbred mice, 237
apomorphine
dopamine agonists
locomotor activity
pharmacogenetics
stereotypy
Incremental repeated acquisition, 431
drug interaction
learning
lever press
Indoleamines, 859
exploratory behavior
habituation
monoamines
vasopressin
Indomethacin, 219
d-amphetamine
operant behavior
prostaglandins
rectal temperature
Induced feeding, 651
beta-adrenergic blockade
food intake inhibition
propranolol
Inescapable shock, 749
analgesia
anxiety
librium
shuttle-escape deficit
Interior colliculus, 145
bicuculline
medial septum
site injection
substantia nigra
thyrotropin releasing hormone
Information systems, s109
computerized bibliographic retrieval
lithium
Ingestive behavior, 507
opiate receptors
pigeons
stereoselectivity
Interoceptive stimuli, 687
drug interaction
exteroceptive stimuli
generalization
pigeons
Intracerebral microinjection, 225
antidepressants
chronic administration
muricide
olfactory bulbectomy
Intravenous infusion, 609
ethanol
reinforcement
self-administration
In vivo studies, 583
d-amphetamine
operant behavior
prostaglandins
Iodine-deficient diets, 561
avoidance
body temperature
dopamine
locomotor activity
Ionophores, s77
alkali metals
ion transport
polyethylene glycols
silacrown ethers
Ion transport, s77
alkali metals
ionophores
polyethylene glycols
silacrown ethers
Isolation, 655
chemoattractant
earthworm wash
snakes
vomeronasal system

Lateralization, 163
DSP-4
spontaneous hyperactivity
Learned helplessness, 481
brain monoamines
pituitary-gonadal axis
Learning
cognition, 231
drug interaction, 431
diazepam, 231
human studies, male, 329
incremental repeated acquisition, 431
lever press, 431
memory, 231
mental rehearsal, 329
psychomotor pefformance, 231
route of administration, 231
tolerance, 329
Lesch-Nyhan syndrome, 459
6-hydroxydopamine
neonatal treatment
neuroleptics
self-mutilation
Lesions, caudate nuclei, 929
cats
dependence
morphine
tolerance
Lesions, electrolytic, 357
conditioned emotional response
dorsal noradrenergic bundle
locus coeruleus
open field
Lesions, fimbria-fornix, 273
acetylcholine depletion
AF64A
ethylcholine aziridinium ion
memory deficits
Lesions, unilateral brain, 913
behavioral effects
cats
morphine
stereotypy
Lever press, 431
drug interaction
incremental repeated acquisition
learning
Levorphanol, 213
amphibians
dextrorphan
drug interaction
morphine
naloxone
opiates
Librium, 749
analgesia
anxiety
inescapable shock
shuttle-escape deficit
Licking, 617
anhedonia paradigm
pimozide
sucrose reward
Lightcycle, 495
aggression
naloxone
saline drinking
social behavior
Lisuride
DOM, 281
dopamine receptors, 185
drug discrimination, 185
drug interaction, 281
LSD, 281
mescaline, 281
operant behavior, 281
Lithium
aldehyde dehydrogenase, s93
alkali metals, s71
anorexia nervosa, s51
brain regions, s87
cesium, s71, s87
chemotherapy-induced neutropenia, s51
computerized bibliographic retrieval, s109
human studies, s65
information systems, s109
metabolizing thyroid cancer, s51

mortality, s93
movement disorders, s57
nephrotoxicity, s65
neurotoxicity, s65
nitrogen dioxide, s93
organic brain syndrome, s65
parkinsonism, s57
pharmacokinetics, s87
potassium, s71
rubidium, s71, s87
sodium, s71
tardive dyskinesia, s57
Lithium chloride toxicosis, 387
alcohol consumption
odor aversion
Locomotor activity
amphetamine, 97
apomorphine, 237
avoidance, 561
body temperature, 197, 561
bombesin, 197
catalepsy, 825
clozapine, 97
contraversive circling, 567
cysteamine, 833
desensitisation, 177
dopamine, 561, 791
dopamine agonists, 237
drug interaction, 177, 501
electrical stimulation, medial forebrain bundle, 567
escape, 809
estrogen, 791
GABA mechanisms, 825
globus pallidus, 825
habituation, 551
hamsters, 369
inbred mice, 237
iodine-deficient diets, 561
motility, 551
neurotensin, 197
nucleus accumbens, 501
open field, 197, 833
opiates, 369
passive avoidance, 809
pharmacogenetics, 237
physostigmine, 551
picrotoxin, 501
postural deviation, 791
psychostimulant, 641
beta-receptor agonists, 177
rotation, 791
sex differences, hamsters, 369
somatostatin, 833
spectral analysis, 551
stereotyped gnawing, 641
stereotypy, 97, 237, 825
stimulus parameters, 567
tachyphylaxis, 177
tetrahydrocannabinol, 641
thioridazine, 97
typical and atypical neuroleptics, 97
Tyr-MIF-1 analogs, 809
Locomotor asymmetries, 73
autoreceptors
circling
substantia nigra
Locus coeruleus, 357
conditioned emotional response
dorsal noradrenergic bundle
lesions, electrolytic
open field
Lordosis, 755
cholecystokinin
sexual behavior, female rats
LSD
DOM, 281, 333
drug interaction, 281, 333
lisuride, 281
mescaline, 281
naloxone, 333
operant behavior, 281, 333
quipazine, 333
LY150720 (picenadol), 779
mixed-agonist-antagonist
opioids
schedule-controlled behavior
squirrel monkeys

Magnitude estimation, 203
cigarettes
human studies
nicotine
preference
taste
Maternal opiate dependence, 555
methadone
morphine
offspring analgesia
MDA, 453
monkeys
phencyclidine
repeated acquisition
Medial septum, 145
bicuculline
inferior colliculus
site injection
substantia nigra
thyrotropin releasing hormone
Memory, 43
avoidance
central cholinergic receptors
diisopropylfluorophosphate
quinuclidinyl benzilate binding
Memory
Alzheimer's disease, 169
avoidance, 169
choline, 209
cognition, 231
diazepam, 231
dementias, 169
diisopropyl fluorophosphate, 467
habituation, 209
learning, 231
muscarinic receptors, 467
nootropics, 209
piracetam, 209
psychomotor performance, 231
[^{3}H]quinclidinyl benzilate binding, 467
retention, 169, 467
route of administration, 231
Memory deficits, 273
acetylcholine depletion
AF64A
ethylcholine aziridinium ion
lesions, fimbria-fornix
Memory spread, 633
beta-adrenergic antagonist
propranolol
quantitative autoradiography
Mental rehearsal, 329
human studies, male
learning
tolerance
Mescaline, 281
DOM
drug interaction
lisuride
LSD
operant behavior
Metabolizing thyroid cancer, s51
anorexia nervosa
chemotherapy-induced neutropenia
lithium
Metals, s41
elements
poisoning
psychiatry
Methadone
fixed-ratio, 743
maternal opiate dependence, 555
morphine, 555
multiple fixed-interval, 743
offspring analgesia, 555
Methamphetamine, 737
monoamines
rhesus monkeys
self-administration
tolerance
Method
cold pressor test, 975
gel chromatography, 761, 969
high performance liquid chromatography, 117, 761, 937
horseradish peroxidase, 301
lever press, 431
operant conditioning, 255
radial arm maze, 273
radioimmunoassay, 937
spectral analysis, 551
up-and-down method, 133
Vogel's conflict test procecedure, 521
Methylamphetamine, 29
caudate nucleus
6-hydroxydopamine
neurotoxicity
Methylxanthines, 375
caffeine
drug interaction
L-phenylisopropyladenosine
variable ratio
Metronidazole, 317
ethanol
neural tolerance
strain differences
MIF, 365
gastrointestinal transit
morphine
naloxone
narcotic antagonism
MIF-1
analgesia, 975
antidepressant drugs, 767
cold pressor pain, 975
depression, 767
human studies, 975
immobility, 767
opiate antagonist, 975
Tyr-MIF-1
Mixed agonist-antagonist, 779
LY150720 (picenadol)
opioids
schedule-controlled behavior
squirrel monkeys
Monkeys, 453
MDA
phencyclidine
repeated acquisition
Monoamines
animal model, 891
cerebral blood flow, 891
cerebrovascular permeability, 891
depression, 891

exploratory behavior, 859
habituation, 859
indoleamines, 859
methamphetamine, 737
rhesus monkeys, 737
self-administration, 737
tolerance, 737
vasopressin, 859
Morbidity, s35
alcohol dehydrogenase
aldehyde dehydrogenase
cesium chloride
ethanol
hepatoma
Morphiceptin, 705
drug interaction
morphine
μ receptor
Morphine
amphibians, 213
analgesia, 79
antinociception, 591
behavioral effects, 913
cats, 913, 923, 929
conditioned taste aversion, 591
dependence, 929
dextrorphan, 213
drug interaction, 213, 705
EEG, 923
gastrointestinal transit, 365
lesions, caudate nuclei, 929
lesions, unilateral brain, 913
levorphanol, 213
maternal opiate dependence, 555
methadone, 555
MIF, 365
morphiceptin, 705
naloxone, 213, 365, 591
narcotic antagonism, 365
offspring analgesia, 555
opiate receptors, 591
opiates, 213
pain, 79
parachlorophenylalanine, 79
μ receptor, 705
sleep-wakefulness, 923
stereotypy, 913
tolerance, 929
Morphine extinction, 545
conditioned place preference
drug reinforcement
Morphine, prenatal exposure, 103
analgesia
avoidance
stress
Morphine withdrawal, 345
DA synthesis
Z-Pro-D-Leu
Mortality
aldehyde dehydrogenase, s93
cesium, s27, s31
hepatoma, s31
lithium, s93
nitrogen dioxide, s93
potassium, s27, s31
sarcoma, s27
tumor, s27
Motility, 551
habituation
locomotor activity
physostigmine
spectral analysis
Mouse killing, 5
naloxone
predation
Movement disorders, 57
lithium
parkinsonism
tardive dyskinesia
Multiple fixed-interval, 743
fixed-ratio
methadone
Multi-unit activity, 53
dexamphetamine
excitatory afferents
striatum
Muricide
adrenoceptors, 267
antidepressants, 225
catalepsy, 267
chlorpromazine, 267
chronic administration, 225
hypothalamus, 267
imipramine, 267
intracerebral microinjection, 225
olfactory bulbectomy, 225
Muscarinic receptors
diisopropyl fluorophosphate, 467
dopamine receptors, 297
memory, 467
nicotinic receptors, 297
[^{3}H]quinclidinyl benzilate binding, 467
retention, 467
tongue protruding, 297
yawning, 297
Muscimol, 89
GABA agonists
self-injurious behavior
self-mutilation

NaCl intake, 449
anxiolytic agents
chlordiazepoxide
punishment attenuation
Naloxone
aggression, 495
amphibians, 213
analgesia, 681
antinociception, 591
apomorphine, 733
brain catecholamines, 733
caffeine, 33
chafing, 727
conditioned taste aversion, 591
dextrorphan, 213
displacement activity, 727
DOM, 333
drug interaction, 213, 333
eating, 33
fish, 727
gastrointestinal transit, 365
levorphanol, 213
lightcycle, 495
LSD, 333
MIF, 365
morphine, 213, 365, 591
mouse killing, 5
narcotic antagonism, 365
neuropeptides, 727
operant behavior, 333
opiate receptors, 591
opiates, 213
opioids, 33
PCPA, 681
predation, 5
purines, 33
quipazine, 333
saline drinking, 495
stereotypy, 733
social behavior, 495
stress, 681
thyrotropin-releasing hormone (TRH), 727
yohimbine, 681
Naltrexone, 423
avoidance
ethanol
opiate antagonists
supersensitivity
Narcotic antagonism, 365
gastrointestinal transit
MIF
morphine
naloxone
Neonatal treatment, 459
6-hydroxydopamine
Lesch-Nyhan syndrome
neuroleptics
self-mutilation
Nephrotoxicity, s65
human studies
lithium
neurotoxicity
organic brain syndrome
Neural tolerance, 317
ethanol
metronidazole
strain differences
Neurohypophyseal peptides, 539
ethanol
tolerance
Neuroleptics
chlorprothixene, 721
delayed-matching-to-sample, 721
haloperidol, 721
6-hydroxydopamine, 459
Lesch-Nyhan syndrome, 459
neonatal treatment, 459
pigeons, 721
self-mutilation, 459
trifluoperazine, 721
Neuropeptides
ACTH, 513
blood pressure, 513
chafing, 727
dishabituation, 513
displacement activity, 727
fish, 727
heart rate, 513
human studies, 513
naloxone, 727
thyrotropin-releasing hormone (TRH), 727
vigilance, 513
Neurotensin, 197
body temperature
bombesin
locomotor activity
open field
Neurotoxicity
caudate nucleus, 29
human studies, s65
6-hydroxydopamine, 29
lithium, s65
methylamphetamine, 29
nephrotoxicity, s65
organic brain syndrome, s65
Neurotransmitter amino acids, 349
brain plasticity
differentially housed mice
Nicotine
activity responses, 675
caffeine, 871
castration, 675

cigarettes, 203
diallel cross, 953
exploration, 871
human studies, 203
hypothermia, 953
magnitude estimation, 203
open field, 871
pharmacogenetics, 953
preference, 203
saccharin, 527
sex differences, 675
strain differences, 953
taste, 203
taste aversion, 527
tolerance, 871
two-bottle choice, 527
wheelrunning, 871
Nicotinic receptors, 297
dopamine receptors
muscarinic receptors
tongue protruding
yawning
Nigroraphe pathway, 301
apomorphine
dopamine autoreceptors
serotonergic neurons
striatum
Nitrogen dioxide, s93
aldehyde dehydrogenase
lithium
mortality
Nociception, 133
analgesia
threshold measurement
up-and-down method
Nociceptive thresholds, 813
cold swim stress
diazepam
flinch jump test
stress-induced analgesia
Nootropics, 209
choline
habituation
memory
piracetam
Norepinephrine, 801
body weight
chronic drug injections
eating
hyperphagia
paraventricular nucleus
Nucleus accumbens, 501
drug interaction
locomotor activity
picrotoxin

Odor aversion, 387
alcohol consumption
lithium chloride toxicosis
Offspring analgesia, 555
maternal opiate dependence
methadone
morphine
Olfactory bulbectomy, 225
antidepressants
chronic administration
intracerebral microinjection
muricide
Ontogeny of rearing, 321
d-amphetamine
catecholamines
scopolamine
Open field
apomorphine, 85
avoidance, 707
body temperature, 197
bombesin, 197
caffeine, 871
conditioned emotional response, 357
corticotropin-releasing factor, 707
cysteamine, 833
dorsal noradrenergic bundle, 357
exploration, 871
lesions, electrolytic, 357
locomotor activity, 197, 833
locus coeruleus, 357
neurotensin, 197
nicotine, 871
organic solvent abuse, 625
plasma-corticosterone levels, 707
social behavior, 85
somatostatin, 833
stereotypy, 85
tolerance, 625, 871
toluene, 625
wheelrunning, 871
Operant behavior
d-amphetamine, 219, 575, 583
blood ethanol levels, 255
body temperature, 575
DOM, 281, 333
drug interaction, 281, 333
ethanol self-selection, 255
indomethacin, 219
in vivo studies, 583
lisuride, 281
LSD, 281, 333
mescaline, 281
naloxone, 333
prostaglandins, 219, 575, 583
quipazine, 333
rectal temperature, 219
Opiate antagonist
analgesia, 937, 975
avoidance, 423
cold pressor pain, 975
ethanol, 423
human studies, 975
MIF-1, 975
naltrexone, 423
supersensitivity, 423
tail-flick, 937
Tyr-MIF-1, 937
Opiate receptors
antinociception, 591
cell harvesters, 947
conditioned taste aversion, 591
filtration, 947
ingestive behavior, 507
morphine, 591
naloxone, 591
pigeons, 507
stereoselectivity, 507
Opiate withdrawal, 699
endorphins
focal brain stimulation
stimulation-produced analgesia
tolerance
Opiates
amphibians, 213
dextrorphan, 213
drug interaction, 213
hamsters, 369
levorphanol, 213
locomotor activity, 369
morphine, 213
naloxone, 213
sex differences, hamsters, 369
Opioids
caffeine, 33
eating, 33
LY150720 (picenadol), 779
mixed agonist-antagonist, 779
naloxone, 33
purines, 33
schedule-controlled behavior, 779
squirrel monkeys, 779
Opioid peptides, 259
behavioral effects
drinking
eating
reward
Organic brain syndrome, s65
human studies
lithium
nephrotoxicity
neurotoxicity
Organic solvent abuse, 625
open field
tolerance
toluene

Pain, 79
analgesia
morphine
parachlorophenylalanine
Pancreatic enzymes, 245
dorsomedial hypothalamic lesions
eating
growth retardation
Parachlorophenylalanine, 79
analgesia
morphine
pain
Paraventricular nucleus, 801
body weight
chronic drug injections
eating
hyperphagia
norepinephrine
Parkinsonism, s57
lithium
movement disorders
tardive dyskinesia
Passive avoidance
blood pressure response, 393
escape, 809
locomotor activity, 809
Tyr-MIF-1 analogs, 809
vasopressin, 393
vasopressin fragments, 393
vasopressor antagonists, 393
PCPA, 681
analgesia
naloxone
stress
yohimbine
PCP-induced stimulation, 159
genetic influences
strain differences
Pentazocine
brain stimulation reward, 961
drug discrimination, 877
drug interaction, 877
mu-receptor, 877
threshold determination, 961
tripelennamine, 877, 961
Peptide
ACTH, 513
arginine vasopressin, 539
bombesin, 197
cholecystokinin, 339, 755

corticotropin (ACTH), 39
corticotropin-releasing factor, 707
delta-sleep inducing peptide, 761, 969
endorphins, 259, 699
met-enkephalin, 943
GABA, 521
[des-9-glycinamide]LVP, 539
MIF-1, 767, 975
neurotensin, 197
somatostatin, 833
THIP, 491
thyrotropin releasing hormone, 145, 715, 727
Try-MIF-1, 767, 937
Tyr-MIF-1-analogs, 809
N-Tyr-MIF-1, 943
vasopressin, 393, 859
Periaqueductal gray, 353
anxiety model
aversive brain stimulation
ethyl alcohol
Perseverative responding, 715
signal detection theory
thyrotropin releasing hormone (TRH)
visual discrimination
Pharmacogenetics
apomorphine, 237
diallel cross, 953
dopamine agonists, 237
hypothermia, 953
inbred mice, 237
locomotor activity, 237
nicotine, 953
stereotypy, 237
strain differences, 953
Pharmacokinetics, s87
brain regions
cesium
lithium
rubidium
Phencyclidine
5-HT release, 401
5-HT uptake, 401
MDA, 453
monkeys, 453
repeated acquisition, 453
serotonergic system, 401
stereotypy, 401
L-Phenylisopropyladenosine, 375
caffeine
drug interaction
methylxanthines
variable ratio
pH Therapy, s25
cancer
cesium
colon carcinoma
diet
Physostigmine
antimuscarinic agents, 109
drug interaction, 109
habituation, 551
locomotor activity, 551
motility, 551
schedule-controlled behavior, 109
spectral analysis, 551
Picrotoxin, 501
drug interaction
locomotor activity
nucleus accumbens
Pigeons
d-amphetamine, 663
chlorprothixene, 721
delayed-matching-to-sample, 721
drug interaction, 687
exteroceptive, 687
generalization, 687
haloperidol, 721
ingestive behavior, 507
interoceptive stimuli, 687
neuroleptic drugs, 721
opiate receptors, 507
short-term memory, 663
stereoselectivity, 507
time perception, 663
trifluoperazine, 721
Pimozide, 617
anhedonia paradigm
licking
sucrose reward
Pineal, 821
benzodiazepines
constant light
superior cervical ganglionectomy
Piracetam, 209
choline
habituation
memory
nootropics
Pituitary-gonadal axis, 481
brain monoamines
learned helplessness
Plasma corticosterone
anxiety, 839
avoidance, 707
benzodiazepines, 839
clorazepate, 839
corticotropin-releasing factor, 707
open field, 707
Ro 15-1788, 839
stress, 839
Poisoning, s41
elements
metals
psychiatry
Polyethylene glycols, s77
alkali metals
ionophores
ion transport
silacrown ethers
Positron radiodetection, s17
cesium
cesium antipsychotic synergism
cesium glucose interaction
cesium vasopressor activity
Postural deviation
dopamine, 791, 979
estrogen, 791
locomotor activity, 791
rearing, 471
rotation, 791, 979
scopolamine, 471
stereotypy, 471
striatum, 979
Potassium
alkali metals, s71
cesium, s27, s31, s71
hepatoma, s31
lithium, s71
mortality, s27, s31
rubidium, s71
sarcoma, s27
sodium, s71
tumor, s27
Potassium supplement, s15
cesium
diet
human studies
vitamins
Precursors, 969
aggregation
DSIP
protein binding
Predation, 5
mouse killing
naloxone
Preference, 203
cigarettes
human studies
magnitude estimation
nicotine
taste
Prenatal stress, 417
adrenergic receptors
tyrosine hydroxylation
Propranolol
beta-adrenergic antagonist, 633
beta-adrenergic blockade, 651
food intake inhibition, 651
induced feeding, 651
memory spread, 633
quantitative autoradiography, 633
Prostaglandins
d-amphetamine, 219, 575, 583
body temperature, 575
indomethacin, 219
in vivo studies, 583
operant behavior, 219, 575, 583
rectal temperature, 219
Protein binding, 969
aggregation
DSIP
precursors
Psychiatry, s41
elements
metals
poisoning
Psychomotor performance, 231
cognition
diazepam
learning
memory
route of administration
Psychostimulant, 641
locomotor activity
stereotyped gnawing
tetrahydrocannabinol
Pulse pressure, s99
carbon monoxide
coronary flow
heart rate
Punishment attenuation, 449
anxiolytic agents
chlordiazepoxide
NaCl intake
Purines, 33
caffeine
eating
naloxone
opioids
Push-pull perfusion, 117
cats
cuneate nucleus
electrical stimulation
superficial radial nerve
Pyrazolodiazepine stress, 487
animal model
depression
zometapine

Quantitative autoradiography, 633
beta-adrenergic antagonist
memory spread

Quinuclidinyl benzilate binding, 43
avoidance
central cholinergic receptors
diisopropylfluorophosphate
memory
[^{3}H]Quinclidinyl benzilate binding, 467
diisopropyl fluorophosphate
memory
muscarinic receptors
retension
Quipazine
DOM, 333
drug interaction, 333
extinction, 533
fluoxetine, 533
LSD, 333
naloxone, 333
operant behavior, 333
serotonin, 533

Rate-dependent drug effects, 67
d-amphetamine
fixed-interval schedules
human studies
verbal behavior
Rearing, 471
postural deviation
scopolamine
stereotypy
Beta-receptor agonists, 177
desensitization
drug interaction
locomotor activity
tachyphylaxis
μ Receptor
drug discrimination, 877
drug interaction, 705, 877
morphiceptin, 705
morphine, 705
pentazocine, 877
tripelennanine, 877
Rectal temperature, 219
d-amphetamine
indomethacin
operant behavior
prostaglandins
Reinforcement, 609
ethanol
intravenous infusion
self-administration
Repeated acquisition, 453
MDA
monkeys
phencyclidine
Repeated treatment, antidepressants, 695
antidepressants
hypoactivity
salbutamol
Respiration rate, s103
blood pressure
carbon monoxide
carboxyhemoglobin
heart rate
Respiratory depression, 289
biogenic amines
2-chloroadenoasine
Retention
Alzheimer's disease, 169
avoidance, 169
dementias, 169
diisopropyl fluorophosphate, 467
memory, 169, 467
muscarinic receptors, 467
[^{3}H]quinclidinyl benzilate binding, 467
Reward, 259
behavioral effects
drinking
eating
opioid peptides
Rhesus monkeys
d-amphetamine, 191
diazepam, 191
greeting behavior, 191
methamphetamine, 737
monoamines, 737
self-administration, 737
social behavior, 191
tolerance, 737
Ro 15-1788
anxiety, 839
benzodiazepines, 839
benzodiazepine antagonism, 381
CGS 8216, 381
chlordiazepoxide, 381
clorazepate, 839
DRL responding, 381
plasma corticosterone, 839
stress, 839
Rotation
dopamine, 791, 979
estrogen, 791
locomotor activity, 791
postural deviation, 791, 979
striatum, 979
Route of administration, 231
cognition
diazepam
learning
memory
psychomotor performance
Rubidium
affective disorders, s49
alkali metals, s71
antidepressants, s49
brain regions, s87
cesium, s71, s87
lithium, s71, s87
pharmacokinetics, s87
potassium, s71
schizophrenia, s49
sodium, s71

Saccharin, 527
nicotine
taste aversion
two-bottle choice
Salbutamol, 695
antidepressants
hypoactivity
repeated treatment, antidepressants
Saline drinking, 495
aggression
lightcycle
naloxone
social behavior
Salt appetite, 883
β-adrenergic antagonists
drinking
drug interaction
Sarcoma, s27
cesium
mortality
potassium
tumor
Schedule-controlled behavior
antimuscarinic agents, 109
drug interaction, 109
LY150720 (picenadol), 779
mixed agonist-antagonist, 779
opioids, 779
physostigmine, 109
squirrel monkeys, 779
Schizophrenia, s49
affective disorders
antidepressants
rubidium
Scopolamine
d-amphetamine, 321
catecholamine, 321
ontogeny of rearing, 321
postural deviation, 471
rearing, 471
stereotypy, 471
Selective attention, 9
blocking
dorsal noradrenergic bundle
drug interaction
Self-administration
cigarettes, 903
ethanol, 609
human studies, 903
intravenous infusion, 609
methamphetamine, 737
monoamines, 737
reinforcement, 609
rhesus monkeys, 737
smoking, 903
temperature, 903
tolerance, 737
Self-injurious behavior, 89
GABA agonists
muscimol
self-mutilation
Self-mutilation
GABA agonists, 89
6-hydroxydopamine, 459
Lesch-Nyhan syndrome, 459
muscimol, 89
neonatal treatment, 459
neuroleptics, 459
self-injurious behavior, 89
Self-stimulation, 667
benzodiazepine
β-carboline
chlordiazepoxide
FG 7142
Self-stimulation, hypothalamus, 773
benzodiazepines
conflict situation
stimulation, dorsal central gray
Serotonergic neurons, 301
apomorphine
dopamine autoreceptors
nigroraphe pathway
striatum
Serotonergic system, 401
5-HT release
5-HT uptake
phencyclidine
stereotypy
Serotonin, 533
extinction
fluoxetine
quipazine
Sex differences, 675
activity responses
castration
nicotine
Sex differences, hamsters, 369
hamsters
locomotor activity
opiates

Sexual behavior, female rats, 755
cholecystokinin
lordosis
Sexual behavior, male rats, 463
apomorphine
dopamine autoreceptors
haloperidol
Short-term memory, 663
d-amphetamine
pigeons
time perception
Shuttle-escape deficit, 749
analgesia
anxiety
inescapable shock
librium
Signal detection theory, 715
perseverative responding
thyrotropin releasing hormone (TRH)
visual discrimination
Silacrown ethers, s77
alkali metals
ionophores
ion transport
polyethylene glycols
Site injection, 145
bicuculline
inferior colliculus
medial septum
substantia nigra
thyrotropin releasing hormone
Sleep, 761
blood
delta-sleep inducing peptide
high performance liquid chromatography
Sleep-wakefulness, 923
cats
EEG
morphine
Smoking, 903
cigarettes
human studies
self-administration
temperature
Snakes, 655
chemoattractant
earthworm wash
isolation
vomeronasal system
Social behavior
aggression, 495
d-amphetamine, 191
apomorphine, 85
diazepam, 191
greeting behavior, 191
lightcycle, 495
naloxone, 495
open field, 85
rhesus monkeys, 191
saline drinking, 495
stereotypy, 85
Social isolation
age differences, 671
aminergic changes, 181
apomorphine, 181, 671
chronic lithium treatment, 181
stereotypy, 671
Sodium, s71
alkali metals
cesium
lithium
potassium
rubidium
Sodium valproate, 845
chlordiazepoxide
conflict
GABA
Somatostatin, 833
cysteamine
locomotor activity
open field
Spectral analysis, 551
habituation
locomotor activity
motility
physostigmine
Spontaneous hyperactivity, 163
DSP-4
lateralization
Squirrel monkeys, 779
LY150720 (picenadol)
mixed agonist-antagonist
opioids
schedule-controlled behavior
Stereoisomers, 61
cannabinoids
drug discrimination
hypothermia
Stereoselectivity, 507
ingestive behavior
opiate receptors
pigeons
Stereotyped gnawing, 641
locomotor activity
psychostimulant
tetrahydrocannabinol
Stereotypy
age differences, 671
amphetamine, 97
apomorphine, 85, 237, 671, 733
behavioral effects, 913
brain catecholamines, 733
catalepsy, 825
cats, 913
clozapine, 97
dopamine agonists, 237
GABA mechanisms, 825
globus pallidus, 825
5-HT release, 401
5-HT uptake, 401
inbred mice, 237
lesions, unilateral brain, 913
locomotor activity, 97, 237, 825
naloxone, 733
open field, 85
pharmacogenetics, 237
phencyclidine, 401
postural deviation, 471
rearing, 471
scopolamine, 471
serotonergic system, 401
social behavior, 85
social isolation, 671
stereotypy, 913
thioridazine, 97
typical and atypical neuroleptics, 97
Stimulation, dorsal central gray, 773
benzodiazepines
conflict situation
self-stimulation, hypothalamus
Stimulation-produced analgesia, 699
endoprhins
focal brain stimulation
opiate withdrawal
tolerance
Stimulus parameters, 567
contraversive circling
electrical stimulation, medial forebrain bundle
locomotor activity
Strain differences
diallel cross, 953
ethanol, 317
genetic influences, 159
hypothermia, 953
metronidazole, 317
neural tolerance, 317
nicotine, 953
PCP-induced stimulation, 159
pharmacogenetics, 953
Stress
analgesia, 103, 681
anxiety, 839
avoidance, 103
benzodiazepines, 839
clorazepate, 839
morphine, prenatal exposure, 103
naloxone, 681
PCPA, 681
plasma corticosterone, 839
Ro 15-1788, 839
yohimbine, 681
Stress-induced analgesia, 813
cold swim stress
diazepam
flinch jump test
nociceptive thresholds
Striatum
apomorphine, 301
dexamphetamine, 53
dopamine, 979
dopamine autoreceptors, 301
excitatory afferents, 53
multi-unit activity, 53
nigroraphe pathway, 301
postural deviation, 979
rotation, 979
serotonergic neurons, 301
Structure-activity relationships, 1
(+)-cathine
(±)-cathinone
drug discrimination
drug interaction
Structure-activity studies, 895
amphetamine analogs
drug discrimination
Subjective effects, 865
benzodiazepines
drug preference
flurazepam
human studies
Substantia nigra
autoreceptors, 73
bicuculline, 145
circling, 73
inferior colliculus, 145
locomotor asymmetries, 73
medial septum, 145
site injection, 145
thyrotropin releasing hormone, 145
Sucrose reward, 617
anhedonia paradigm
licking
pimozide
Superior cervical ganglionectomy, 821
benzodiazepines
constant light
pineal
Superficial radial nerve, 117
cats
cuneate nucleus

electrical stimulation
push-pull perfusion
Superior colliculus, 853
circling
GABA agonists
Supersensitivity, 423
avoidance
ethanol
naltrexone
opiate antagonists

Tachyphylaxis, 177
desensitisation
drug interaction
locomotor activity
beta-receptor agonists
Tail-flick, 937
analgesia
opiate antagonist
Tyr-MIF-1
Tardive dyskinesia, s57
lithium
movement disorders
parkinsonism
Taste, 203
cigarettes
human studies
magnitude estimation
nicotine
preference
Taste aversion, 527
nicotine
saccharin
two-bottle choice
Temperature, 903
cigarettes
human studies
self-administration
smoking
Tetrahydrocannabinol, 641
locomotor activity
psychostimulant
stereotyped gnawing
Thioridazine, 97
amphetamine
clozapine
locomotor activity
stereotypy
typical and atypical neuroleptics
THIP, 491
anticonvulsion
electroconvulsive shock
hypothermia
Threshold determination, 961
brain-stimulation reward
pentazocine
tripelennamine
Threshold measurement, 133
analgesia
nociception
up-and-down method
Thyrotropin-releasing hormone (TRH)
bicuculline, 145
chafing, 727
displacement activity, 727
fish, 727
inferior colliculus, 145
medial septum, 145
naloxone, 727
neuropeptides, 727
perseverative responding, 715
signal detection theory, 715
site injection, 145
substantia nigra, 145
visual discrimination, 715
Time perception, 663
d-amphetamine
pigeons
short-term memory
Tolerance
caffeine, 871
cats, 929
dependence, 929
depressant effects, 409
diazepam, 409
drug discrimination, 409
endorphins, 699
ethanol, 539
exploration, 871
fixed ratio schedule, 409
focal brain stimulation, 699
human studies, male, 329
learning, 329
lesions, caudate nuclei, 929
mental rehersal, 329
methamphetamine, 737
monoamines, 737
morphine, 929
neurohypophyseal peptides, 539
nicotine, 871
open field, 625, 871
opiate withdrawal, 699
organic solvent abuse, 625
rhesus monkeys, 737
self-administration, 737
stimulation-produced analgesia, 699
toluene, 625
wheelrunning, 871
Tongue protruding, 297
dopamine receptors
muscarinic receptors
nicotinic receptors
yawning
Toluene, 625
open field
organic solvent abuse
tolerance
Trifluoperazine, 721
chlorprothixene
delayed-matching-to-sample
haloperidol
neuroleptic drugs
pigeons
Tripelennamine
brain-stimulation reward, 961
drug discrimination, 877
drug interaction, 877
pentazocine, 877, 961
mu-receptor, 877
threshold determination, 961
Tumor
cancer therapy, s1
cesium, s1, s27
high pH, s1
human studies, s1
mortality, s27
potassium, s27
sarcoma, s27
vitamins, s1
Two-bar press, 19
discrimination
drug discrimination
fixed-ratio schedule
Two-bottle choice, 527
nicotine
saccharin
taste aversion

Typical and atypical neuroleptics, 97
amphetamine
clozapine
locomotor activity
stereotypy
thioridazine
Tyr-MIF-1
analgesia, 937
antidepressant drugs, 767
depression, 767
immobility, 767
MIF-1, 767
opiate antagonist, 937
tail-flick, 937
Tyr-MIF-1 analogs, 809
escape
locomotor activity
passive avoidance
N-tyrosinated peptides, 943
blood-brain barrier
carrier-mediated transport
Tyrosine hydroxylation, 417
adrenergic receptors
prenatal stress

Up-and-down method, 133
analgesia
nociception
threshold measurement
Urinary excretion, 125
adrenal gland
catecholamines
ethanol

Vagal afferents, 441
antinociception
enkephalinamide
Variable ratio, 375
caffeine
drug interaction
methylxanthines
L-phenylisopropyladenosine
Vasopressin
blood pressure, 393
exploratory behavior, 859
habituation, 859
indoleamines, 859
monoamines, 859
passive avoidance, 393
vasopressin fragments, 393
vasopressor antagonists, 393
Vasopressin fragments, 393
blood pressure response
passive avoidance
vasopressin
vasopressor antagonists
Vasopressor antagonists, 393
blood pressure response
passive avoidance
vasopressin
vasopressin fragments
Verbal behavior, 67
d-amphetamine
fixed-interval schedules
human studies
rate-dependent drug effects
Vigilance, 513
ACTH
blood pressure
dishabituation
heart rate
human studies
neuropeptides

Visual discrimination, 715
perseverative responding
signal detection theory
thyrotropin releasing hormone (TRH)
Vitamins
antioxidants, s7
cancer, s7, s11
cancer therapy, s1
cesium, s1, s7, s11, s15
diet, s7, s11, s15
essential fatty acids, s7
high pH, s1
human studies, s1, s11, s15
potassium supplement, s1, s15
tumors, s1
Voluntary intake of ethanol, 787
drinking
GABA
homotaurine
Vomeronasal system, 655
chemoattractant
earthworm wash
isolation
snakes
Water-deprivation, 47
circadian cycle
drinking
ethylketocyclazocine
Wheelrunning, 871
caffeine
exploration
nicotine
open field
tolerance
Yawning, 297
dopamine receptors
muscarinic receptors
nicotinic receptors
tongue protruding
Yohimbine, 681
analgesia
naloxone
PCPA
stress
Z-Pro-D-Leu, 345
DA synthesis
morphine withdrawal
Zometapine, 487
animal model
depression
pyrazolodiazepine stress

AUTHOR INDEX

Abel, D. A., 767
Adams, M. A., 125
Adler, C. M., 609
Ahlenius, S., 463
Akins, F. R., 687
Albert, D. J., 5
Altman, H., 467
Amano, M., 401
Ammassari-Teule, M., 103
Andrews, J. S., 715
Arkles, B., s77
Asdourian, D., 853

Baldino, F., Jr., 137
Banks, W. A., 943
Baudhuin, M. G., s109
Bauer, R. H., 321
Baumeister, A. A., 89, 459
Baran, L., 695
Bardo, M. T., 545, 591
Barela, P., 369
Beck, C. H. M., 85
Belkien, L., 481
Bell, M., 481
Beninger, R. J., 533
Bernardis, L. L., 245
Bernet, F., 357
Bhargava, H. N., 365
Bigajska, K., 695
Bloom, A. S., 733
Bodnar, R. J., 79
Boismare, F., 787
Bollók, I., 833
Bose, R., s17
Bovier, Ph., 353
Born, J., 513
Breese, G. R., 145, 289, 459
Brewer, A. K., s1, s25
Brezenoff, H. E., 109
Broekkamp, C. L., 353
Brooks, S., 245
Bruins, L., 197
Bryant, H. U., 651
Bryson, R., 675
Burch, J. B., 953
Burgess, J. W., 913, 923, 929

Campbell, I. C., 671
Campbell, J., 891
Carney, J. M., 237, 375, 381
Carter, R. B., 779
Castellano, C., 103
Castellanos, P. F., 969
Caza, P. A., 9
Cervo, L., 737
Chambers, L. K., 471
Cherkin, A., 169
Chitkara, B., 671
Chow, H. L., 85
Chretien, P., 787
Christ, H., 727
Church, A. C., 633
Cleary, J., 743
Coderre, T. J., 681
Collins, A. C., 953
Collins, K. R., 617
Commissaris, R. L., 333
Cooper, S. J., 47
Cordoba, F., 349
Coy, D. H., 767, 809
Crocker, A. D., 133, 561
Crocker, J. M., 561
Cronan, T., 675
Croskell, H., 891
Crump, S., 159

Damjanov, I., 317
Danti, S., 313
Dantzer, R., 839
Daoust, M., 787
de Andres, I., 913, 923, 929
De Jong, W., 393
Deviche, P., 507
Dewey, W. L., 61, 877
De Wied, D., 393, 707
de Wit, H., 865
Drugan, R. C., 749
Dum, J., 259
Durcan, M. J., 671
Durlach, J., 787
Dyer, R. S., 599
Dykstra, L. A., 779

Ehrensing, R. H., 767, 937, 975
Emerick, S. G., 459
Engel, J. A., 521

Fahn, S., 79
Falk, J. L., 449, 965
Fehm, H.-L., 513
Fehn-Wolfsdorf, G., 513
File, S. E., 667
Fischman, A. J., 761, 809, 937, 969
Flexner, J. B., 633
Flexner, L. B., 633
Flood, J. F., 169
Fowler, S. C., 617
Frances, H., 177, 313
Frankenheim, J., 43
Franklin, K. B. J., 73
Freed, W. J., 159
Fregly, M. J., 883
Frye, G. D., 89, 145, 459
Fulker, D. W., 953
Furukawa, H., 401
Furukawa, T., 297

Gaffori, O., 393
Galizio, M., 423
Gardner, R., 43
Geller, H. M., 137
Geula, C., 853
Geyer, M. A., 301
Ghoneim, M. M., 231
Giknis, M. L. A., 317
Glennon, R. A., 1, 895
Gold, R., 501
Goldfinger, M. D., 117
Goldschmidt, P. L., 177
Gomita, Y., 773
Gonzalez, L. P., 551
Gorzalka, B. B., 755
Gouvier, W. D., 687
Graf, M. V., 761, 767, 969
Gramling, S. E., 617
Greist, J. H., s109
Griffiths, R. R., 903
Grupp, L. A., 255

Halpern, M., 655
Hara, C., 267
Harris, C. M., 913, 929
Harris, L. S., 61
Hauck, A. E., 895
Haug, T., 409
Hayashi, T., 809
Hayes, M. W., 19
Hellhammer, D. H., 481
Henck, J. W., 333
Herberg, L. J., 667
Herz, A., 259
Hetzler, B. E., 599
Hinman, D. J., 625
Hinrichs, J. V., 231
Hiramatsu, M., 401
Hirst, M., 125
Hódi, K., 345
Hoffman, P. L., 539
Höglund, A. U., 859
Honor, J., 743
Hovious, J. R., 555
Hughes, C. W., 891
Hymowitz, N., 109

Ichimaru, Y., 773
Inoue, T., 297
Iwamoto, E. T., 527

Jähkel, M., 181
Jalfre, M., 209
Janowsky, D. S., 641
Jarrard, L. E., 273
Jefferson, J. W., s109
Jeste, D. V., 159
Johanson, C. E., 737, 865
Johnson, P., 237
Joyce, J. N., 791, 979

Kádár, T., 339
Kaempf, G. F., 61
Kallman, M. J., 61, 877
Kameyama, T., 401
Kant, G. J., 273
Kastin, A. J., 761, 767, 809, 937, 943, 947, 969, 975
Katz, R. J., 487
Kelly, D. D., 813
Kent, T. A., 891
Király, C., 833
Kirschenbaum, D. M., 655
Klein, D. C., 821
Klein, M. J., 191
Koob, G. F., 641

Kordower, J. H., 79
Kornetsky, C., 645, 961
Kovács, G. L., 345
Krespan, B., 137
Kubos, K. L., 163

La Neave, C. K., s77
Larsson, K., 463
Lawson, C. A., 561
Lebenthal, E., 245
Lee, E. H. Y., 301
Lee, P. C., 245
Leibowitz, S. F., 801
Leitner, D. S., 813
Lemme, P., 501
Lerer, B., 467
Levine, A. S., 33
Leviseur, C., s103
Levy, A., 273
Lhuintre, J. P., 787
Liljequist, S., 521
Lloyd, K. G., 353
Logan, L., 375
Loke, W. H., 871
Loss, M., 43
Ludwig, M., 481

McCown, T. J., 145, 459
McGrath, J., s93, s99, s103
McIntosh, G. H., 561
McKenney, J. D., 895
McKenzie, G. M., 53
McLanahan, K., 237
McMaster, S. B., 641
McMillan, D. E., 431
McNair, E., 675

MacDonald, C., 97
Maier, S. F., 749
Maixner, W., 441
Malek-Ahmadi, P., s49
Malven, P. V., 651
Marks, M. J., 953
Martin, B. R., 61, 877
Meliska, C. J., 871
Mende, T., 501
Mendelson, S. D., 755
Messiha, F. S., s27, s31, s35, s87, s93, s113
Mewaldt, S. P., 231
Meyerhoff, J. L., 273
Meyerson, B. J., 859
Michell, G. F., 975
Milhaud, C. L., 191
Miller, J. S., 545, 591
Minchin, M. C. W., 491
Miner, L., 953
Minor, T. R., 749
Moerschbaecher, J. M., 453
Mokler, D. J., 281, 333
Molina, J. C., 387
Montero, E., 791
Moore, N., 787
Moran, T. H., 163
Morgenstern, R., 501
Moriyama, M., 773
Morley, J. E., 33
Mormede, P., 839
Moss, D. E., 641
Mueller, R. A., 145, 289, 459
Muñoz-Blanco, J., 349

Nabeshima, T., 401
Nagy, A., 833
Nakamura, M., 381
Nakanishi, H., 225
Naparzewska, A. M., 609
Neisewander, J. L., 545
Nemeth-Coslett, R., 903
Nielsen, J. A., 219, 575, 583
Neulieb, R., s15
Noda, Y., 297
Noteboom, J. L., 197
Numan, R., 609
Nutt, D. J., 491

Oehler, J., 181
Oelssner, W., 501
Oke, A., 891
Ossowska, K., 825
Overstreet, D. H., 561
Overton, D. A., 19

Pannell, K. H., s77
Paragas, M. G., s65
Paterson, A. T., 495
Paule, M. G., 431
Pawelec, C., 209
Pellow, S., 667
Penke, B., 339, 833
Perio, A., 839
Peters, D. A. V., 417
Peters, M. A., 555
Pezalla, P. D., 213
Picker, M., 721
Pillai, N. P., 365
Pinsky, C., s17
Platel, A., 209
Poling, A., 721
Porsolt, R. D., 209
Preskorn, S. H., 891
Proffitt, J. K., 969
Przegaliński, E., 695
Puech, A.-J., 313

Quock, R. M., 733

Rainbow, T. C., 633
Ramanjaneyulu, R., 151
Randich, A., 441
Rawana, E., 329
Ray, R., 43
Razdan, R. K., 61
Rea, M. A., 481
Rech, R. H., 281, 333
Reches, A., 79
Redington, K., 203
Rennert, O. M., 237
Resch, G. E., 117
Rico, E., s77
Rinkel, G. J. E., 197
Risner, M. E., 591
Roberts, L. A., s81
Robertson, A., 97
Robichaud, R., 43
Robinson, R. G., 163
Rockstroh, B., 513
Rollman, G. B., 681
Roossin, P., 801
Rosecrans, J. A., 1
Rosenn, M., 801
Roux, S., 209
Russell, R. W., 133
Ryan, S. M., 749

Saad, K. M., 163
Sadowski, J. A., 733
Sahgal, A., 715
Saligaut, C., 787
Sartori, H. E., s7, s11
Schechter, M. D., 1, 185
Schiebe, M., 513
Schijff, J. A., 197
Schmidt, J., 181
Schnur, P., 369
Schulman, N., 655
Scribani, L., 655
Seale, T. W., 237
Seiden, L. S., 29
Serwatka, J., 387
Shibata, S., 225
Shook, J. E., 877
Simon, P., 177, 313
Simpson, C. W., 117
Siwanowicz, J., 695
Skolnick, P., 821
Smaltz, S. C., 423
Smith, G. E., 169
Sparber, S. B., 219, 575, 583
Spear, N. E., 387
Spencer, B. A., 423
Spetch, M. L., 663
Spit, M. C., 197
Stanley, M., 467
Stephens, E., 937
Stevens, C. W., 213
Stewart, R. B., 255
Stitzer, M. L., 67
Stocco, D. M., s31
Sudakov, S. K., 339

Tabakoff, B., 539
Tang, M., 449, 965
Telegdy, G., 339, 345, 833
Thierry, B. H., 191
Thomas, J., 721
Thompson, D. M., 453
Thompson, T., 743
Thorn, B. E., 699
Ticku, M. K., 151
Tokunaga, T., 297
Trapold, M. A., 687
Treit, D., 663
Tufte, F. W., s25
Tufte, M. J., s25
Turkish, S., 47

Ueki, S., 225, 267
Uhlenhuth, E. H., 865
Unterwald, E. M., 961
Ushijima, I., 297

Vaccarino, F. J., 73
van der Heyden, J. A. M., 567
van Hartesveldt, C., 471, 791, 979
Van Ree, J. M., 393
van Wimersma Greidanus, Tj. B., 197
van Zummeren, M., 197
Varga, J., 833
Várszegi, M., 339
Vécsei, L., 833
Veldhuis, H. D., 707
Vellucci, S. V., 39, 845
Verchota, S., 743
Verleye, M., 357
Vickers, C., 495
Villablanca, J. R., 913, 923, 929
Villiger, J. W., 705
Vogel-Sprott, M., 329
Voigt, K. H., 513
Vosmer, G., 29

Wager-Srdar, S., 33
Wallace, K., 43
Wallace, M. M., 79
Walsh, M. L., 5
Warenycia, M. W., 53
Watanabe, S., 225, 267
Webster, R., 329
Webster, R. A., 845
Wędzony, K., 825
Weissman, B. A., 821
Wheeling, H. S., 645
White, R., 5
Widerlöv, E., 289
Williams, D. A., 699
Williams, J. A., s49
Williamson, E. C., 527
Wohland, A., 507
Wolfarth, S., 825
Woolverton, W. L., 737

Yamada, K., 297
Yamaguchi, K., 401
Yim, G. K. W., 651
Young, R., 895
Yung, C. Y., s41, s51, s57, s71
Yusta, B., 349

Zadina, J. E., 947